Modeling Principle

The Mouse Ishikawa Model is an internationally recognized gold-standard in vivo model for research on well-differentiated endometrioid adenocarcinoma, hormone-dependent gynecological tumors, ER/PR pathway regulation and endocrine resistance mechanisms. Derived from human endometrioid adenocarcinoma, Ishikawa cells belong to type I endometrial carcinoma with the highest clinical prevalence, exhibiting typical biological characteristics of well-differentiated endometrial cancer, including stable high expression of estrogen receptor (ER) and progesterone receptor (PR), significant hormone-dependent proliferation, moderate malignancy, high differentiation and stable invasion and metastasis phenotypes. It faithfully recapitulates the pathological progression of clinical hormone-driven endometrial carcinoma, including tumor initiation, proliferation, progression and endocrine therapy resistance. Compared with other endometrial cancer cell lines, Ishikawa cells possess the most clinically consistent phenotypes, intact functional ER/PR signaling, sensitive hormone response, stable in vitro culture characteristics and excellent in vivo tumor homogeneity. It serves as a benchmark cell line for exploring endometrial cancer hormone regulation, ER/PR pathway abnormality, tumor proliferation and invasion, endocrine resistance, targeted sensitization and combined medication. Logarithmic-phase low-passage Ishikawa cells are subcutaneously inoculated into BALB/c-nu immunodeficient nude mice to establish standardized subcutaneous xenograft models with high tumorigenicity, stable phenotypes, reliable hormone response and robust data reproducibility. This model fully meets the standardized methodological writing requirements of NSFC projects, postgraduate proposals, dissertations and high-score SCI manuscripts, and complements ovarian and cervical cancer models to form a complete gynecological tumor research system.

Model Validation Criteria

Quantitative Criteria for Tumor Formation and Growth

1. Positive modeling criteria: Clear macroscopic tumor nodules appear 5–7 days after Ishikawa cell subcutaneous inoculation. The tumor formation rate is ≥95% within 12 days, and tumor volume ＞50 mm³ is defined as successful modeling. Tumors in the vehicle control group proliferate continuously and stably without spontaneous regression, accurately reproducing the malignant characteristics of hormone-driven and persistent proliferation of clinical well-differentiated endometrioid endometrial carcinoma.

2. Model reproducibility criteria: The intra-group coefficient of variation (CV) of tumor volume in the vehicle control group is ＜30%, indicating high standardized modeling operation, minimal individual differences and excellent batch stability, fully meeting the quality control requirements of SCI experimental data.

3. Pharmacodynamic response criteria: After intervention with endometrial cancer positive endocrine/chemotherapeutic drugs, the tumor growth inhibition rate (TGI) is ≥35%, and tumor volume and tumor weight are significantly reduced compared with the vehicle control group (P＜0.05). The model has stable and sensitive pharmacodynamic responses to hormone pathway inhibitors, endocrine sensitizers and chemotherapeutic drugs, suitable for drug screening and drug resistance mechanism verification of hormone-dependent endometrial cancer.

Histopathological and Molecular Gold-Standard Indexes

1. HE staining gold standard: Tumor tissues contain a large number of atypical endometrial glandular epithelial cells with disordered glandular structure, large deeply stained nuclei, clear nucleoli, visible mitotic figures and dense cell arrangement, which conform to the typical histological morphological characteristics of human well-differentiated endometrioid endometrial carcinoma.

2. Molecular phenotypic criteria: Stable high expression of ER and PR proteins and moderately elevated Ki-67 proliferation index in tumor tissues indicate typical hormone-dependent proliferation phenotypes; partial down-regulation of E-cadherin and mild up-regulation of Vimentin, MMP2 and MMP9 present characteristic weak EMT and progressive invasion phenotypes of well-differentiated endometrial cancer, perfectly recapitulating the core molecular pathological characteristics of hormone abnormality-driven slow malignant progression and late drug-resistant recurrence of clinical type I endometrial carcinoma.

3. Pharmacodynamic response criteria: Compared with the vehicle control group, the treatment group shows down-regulated ER/PR expression, decreased Ki-67 proliferation index, increased Cleaved-Caspase-3 apoptosis level and declined expression of EMT and invasion markers, confirming that drugs can target and regulate hormone pathways, inhibit endometrial cancer proliferation, reverse endocrine resistance and block malignant invasive progression.

4. Evidence closed-loop criteria: In vivo histopathological and molecular protein detection results are highly consistent with the in vitro Ishikawa cell experimental mechanism trend, forming a complete and credible academic evidence closed-loop.

Academic Evidence for Model Validity

The Mouse Ishikawa Model is an internationally authoritative gold-standard in vivo model for research on type I endometrioid endometrial carcinoma, hormone-dependent gynecological tumors, ER/PR pathway disorder and endocrine resistance mechanisms. Core academic validity evidence: ① As a classic representative cell line of the most prevalent clinical well-differentiated endometrioid carcinoma, Ishikawa cells stably retain functional ER/PR hormone pathways and accurately simulate the pathological process of hormone disorder-induced carcinogenesis, continuous proliferation and therapeutic resistance; ② It presents stable in vivo tumorigenesis, typical pathological phenotypes, sensitive hormone response and mild and stable malignant progression without batch phenotypic drift, with excellent data reproducibility; ③ It has clear gradient pharmacodynamic responses to endocrine drugs, hormone pathway regulators and chemotherapy sensitizers, serving as a core tool model for endometrial cancer translational medicine and drug resistance mechanism research; ④ It exclusively covers the research dimension of hormone-dependent malignant progression in gynecological tumors and makes up for the shortage of non-hormone-driven phenotypes in ovarian and cervical cancer models; ⑤ It has been widely accepted by top SCI journals in the field of gynecological oncology for decades. As a benchmark model for basic research, endocrine resistance analysis and targeted new drug development of endometrial cancer, it improves the complete gynecological tumor research system.

Model Advantages

The Mouse Ishikawa Model is the exclusive SCI gold-standard benchmark model for research on clinical type I endometrioid endometrial carcinoma, hormone-dependent tumors and endocrine resistance. Core advantages: It accurately corresponds to the most prevalent and representative well-differentiated endometrioid endometrial carcinoma, perfectly simulating the core pathological mechanism of tumor initiation, progression and drug-resistant recurrence driven by clinical estrogen/progesterone disorder. With intact ER/PR pathways, sensitive hormone response and extremely stable phenotypes, it is the most clinically consistent in vivo model for endometrial cancer hormone mechanism research. It features mild and homogeneous tumorigenesis, extremely low batch error and high data signal-to-noise ratio, suitable for in-depth mechanism exploration of high-score SCI papers and innovative design of NSFC hormone-related tumor projects. It can exclusively carry out characteristic research on hormone regulation, endocrine sensitization and drug resistance reversal of gynecological tumors, filling the research gaps that cannot be covered by ovarian and cervical cancer models. Combined with SK-OV-3 and SiHa models, it achieves full coverage of the three major gynecological malignant tumors (ovarian, cervical and endometrial), maximizing the completeness, innovation and fund recognition of research projects.

Research Applications

The Mouse Ishikawa Model is mainly applied to preclinical translational research on hormone regulation mechanisms, endocrine resistance, ER/PR pathway disorder, malignant proliferation and invasion, and targeted sensitization of human type I well-differentiated endometrioid endometrial carcinoma. Core application scenarios: molecular mechanism analysis of estrogen and progesterone disorder-driven endometrial carcinogenesis; research on continuous tumor proliferation and malignant progression mediated by abnormal ER/PR signaling pathways; exploration of the generation and reversal mechanisms of endocrine therapy resistance in endometrial cancer; in vivo efficacy evaluation of innovative drugs used alone or in combination to achieve endocrine sensitization, anti-proliferation, anti-invasion, toxicity reduction and efficacy enhancement. It exclusively compensates for the research shortcomings of hormone-dependent gynecological tumors, and forms a **complete standardized model system for the three major gynecological tumors** when combined with ovarian and cervical cancer models. It fully supports innovative mechanism exploration for NSFC projects, postgraduate proposals, dissertations and high-score SCI papers in multiple directions of gynecological tumor endocrine, targeting, drug resistance and invasion-metastasis research.

Ishikawa cell, human endometrial carcinoma, endometrioid adenocarcinoma, ER/PR positive, hormone-dependent tumor, well-differentiated endometrial cancer, proliferation and invasion, hormone resistance, subcutaneous xenograft model, endometrial cancer targeted and endocrine therapy, preclinical efficacy evaluation